It is a fearsome time for general counsel and chief compliance officers at drug companies, as aggressive federal prosecutors are increasing scrutiny—as well as indictments—over their work.
Joshua Robbins, a former federal health care prosecutor and now chair of the white collar defense and government investigations practice at Greenberg Gross in Los Angeles, noted that a “government press release in one recent case said it wanted ‘to send shock waves’ through the pharmaceutical industry” when it indicted a company and two executives in April over illegally distributing opioids.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]